Patents by Inventor Qiyue Hu

Qiyue Hu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190315886
    Abstract: Provided are a thrombin antibody, an antigen-binding fragment and a pharmaceutical use thereof. Further provided are a chimeric antibody and a humanized antibody comprising a thrombin antibody CDR region, and a pharmaceutical composition comprising the thrombin antibody and the antigen-binding fragment thereof, as well as the use thereof as an anticoagulant drug. In particular, provided is a use of the humanized thrombin antibody in preparing a drug for treating a thrombin-mediated disease or condition.
    Type: Application
    Filed: February 3, 2017
    Publication date: October 17, 2019
    Inventors: Hua YING, Jiajian LIU, Yayuan FU, Ling ZHANG, Haoying ZHANG, Jiakang SUN, Lianshan ZHANG, Weikang TAO, Piaoyang SUN, Qiyue HU
  • Patent number: 10398689
    Abstract: The present invention relates to a benzopiperidine derivative, a preparation method thereof and a medical use thereof. In particular, the present invention relates to a benzopiperidine derivative as shown by general formula (I), a preparation method thereof and a pharmaceutical composition containing the derivative, as well as a use thereof as an estrogen receptor modulator in the prevention and/or treatment of estrogen receptor-mediated or dependent diseases or conditions. Preferably, the disease is breast cancer. The substituents in the general formula (I) are the same as those defined in the description.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: September 3, 2019
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Fanglong Yang, Ling Zhang, Chunfei Wang, Mingxun He, Qiyue Hu, Feng He, Weikang Tao, Piaoyang Sun
  • Publication number: 20190233513
    Abstract: Provided are a LAG-3 antibody, an antigen-binding fragment thereof, and a pharmaceutical application thereof. Further, provided are a chimeric antibody comprising a CDR of the LAG-3 antibody, a humanized antibody, a pharmaceutical composition comprising the LAG-3 antibody and the antigen-binding fragment thereof, and an application of the pharmaceutical composition as an antineoplastic drug. Particularly, provided is an application of a humanized LAG-3 antibody in preparation of drugs for treatment of diseases involving immune cells.
    Type: Application
    Filed: June 22, 2017
    Publication date: August 1, 2019
    Inventors: Zhuoxiao Cao, Yayuan Fu, Qiyue Hu, Weikang Tao, Lianshan Zhang, Piaoyang Sun
  • Patent number: 10323037
    Abstract: The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: June 18, 2019
    Assignee: JIANGSU HENGRUI MEDICINE CO., LTD.
    Inventors: Dong Liu, Minsheng Zhang, Qiyue Hu
  • Publication number: 20190070264
    Abstract: An interleukin 15 (IL-15) protein complex is provided. The IL-15 protein complex includes soluble fusion proteins (I) and (II), wherein the fusion protein (I) is an IL-15 polypeptide or a functional fragment thereof, and the soluble fusion protein (II) is an IL-15R? polypeptide or a functional fragment thereof. The soluble fusion protein (I) has at least one amino acid residue mutated to a cysteine (Cys) residue, which pairs with a corresponding mutated Cys residue on the soluble fusion protein (II), or vice versa, to form one or more disulfide bonds. The IL-15 protein complex can be used for tumor therapy.
    Type: Application
    Filed: November 17, 2015
    Publication date: March 7, 2019
    Applicants: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xiangdong QU, Xin YE, Qiyue HU, Dongbing CUI, Weikang TAO, Lianshan ZHANG, Piaoyang SUN
  • Publication number: 20190016825
    Abstract: The present invention provides a PCSK9 antibody, an antigen-binding fragment thereof, and a medicinal application thereof. Provided in the invention is a chimeric antibody and a humanized antibody, both comprising a CDR of the PCSK9 antibody, and a pharmaceutical composition comprising the PCSK9 antibody and an antigen-binding fragment thereof, and an application of the PCSK9 antibody as a lipid-lowering agent. The invention specifically relates to an application of a humanized PCSK9 antibody for preparing a pharmaceutical drug to treat a PCSK9-induced disease or symptom.
    Type: Application
    Filed: December 20, 2016
    Publication date: January 17, 2019
    Inventors: Xiangdong QU, Xin YE, Shaoyu XU, Bei YUAN, Dongbing CUI, Qiyue HU, Lei ZHANG, Zhibin XU, Weikang TAO, Lianshan ZHANG, Piaoyang SUN
  • Publication number: 20180334504
    Abstract: The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.
    Type: Application
    Filed: November 2, 2016
    Publication date: November 22, 2018
    Applicants: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Xiangdong QU, Qiyue HU, Shaoyu XU, Dongbing CUI, Houcong JIN, Weikang TAO, Lianshan ZHANG, Guoqing CAO, Piaoyang SUN
  • Publication number: 20180318284
    Abstract: The present invention relates to a benzopiperidine derivative, a preparation method thereof and a medical use thereof. In particular, the present invention relates to a benzopiperidine derivative as shown by general formula (I), a preparation method thereof and a pharmaceutical composition containing the derivative, as well as a use thereof as an estrogen receptor modulator in the prevention and/or treatment of estrogen receptor-mediated or dependent diseases or conditions. Preferably, the disease is breast cancer. The substituents in the general formula (I) are the same as those defined in the description.
    Type: Application
    Filed: December 2, 2016
    Publication date: November 8, 2018
    Inventors: Fanglong YANG, Ling ZHANG, Chunfei WANG, Mingxun HE, Qiyue HU, Feng HE, Weikang TAO, Piaoyang SUN
  • Patent number: 10081629
    Abstract: Amide derivatives and pharmaceutically acceptable salts thereof, preparation method thereof and medicinal application thereof are provided. Specifically, amide derivatives represented by general formula (I) are provided. The amide derivatives represented by general formula (I) can be used as a therapeutic agent, particularly as an inhibitor for microsomal prostaglandin E synthase-1 (mPGES-1), and also to treat and/or prevent diseases or illnesses such as inflammation and/or pain etc. The definition of each substituent group in general formula (I) is the same as the definition in the description.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: September 25, 2018
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xin Li, Wei He, Xianbo Liu, Bin Wang, Qiyue Hu, Fangfang Jin, Qing Dong, Piaoyang Sun
  • Publication number: 20180251465
    Abstract: The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.
    Type: Application
    Filed: February 27, 2018
    Publication date: September 6, 2018
    Applicant: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Dong LIU, Minsheng ZHANG, Qiyue HU
  • Patent number: 9951077
    Abstract: The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: April 24, 2018
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Dong Liu, Minsheng Zhang, Qiyue Hu
  • Publication number: 20170152264
    Abstract: The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.
    Type: Application
    Filed: October 20, 2014
    Publication date: June 1, 2017
    Applicant: ETERNITY BIOSCIENCE INC.
    Inventors: Dong LIU, Minsheng ZHANG, Qiyue HU
  • Patent number: 9637484
    Abstract: Cycloalkyl acid derivatives, a preparation method thereof, and a pharmaceutical application thereof are described. In particular, a cycloalkyl acid derivative represented by general formula (I) and a medical salt thereof, a preparation method thereof, and an application of the cycloalkyl acid derivative and the medical salt thereof as URAT1 inhibitors, and particularly as therapeutic agents for diseases related to an abnormal uric acid level are described, wherein definitions of substituent groups in general formula (I) are the same as the definitions in the specification.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: May 2, 2017
    Assignees: SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD., JIANGSU HENGRUI MEDICINE CO., LTD.
    Inventors: Jianbiao Peng, Piaoyang Sun, Jiong Lan, Chunyan Gu, Xiaotao Li, Bonian Liu, Chunzhou Han, Qiyue Hu, Fangfang Jin, Qing Dong, Guoqing Cao
  • Publication number: 20170037044
    Abstract: Amide derivatives and pharmaceutically acceptable salts thereof, preparation method thereof and medicinal application thereof are provided. Specifically, amide derivatives represented by general formula (I) are provided. The amide derivatives represented by general formula (I) can be used as a therapeutic agent, particularly as an inhibitor for microsomal prostaglandin E synthase-1 (mPGES-1), and also to treat and/or prevent diseases or illnesses such as inflammation and/or pain etc. The definition of each substituent group in general formula (I) is the same as the definition in the description.
    Type: Application
    Filed: March 31, 2015
    Publication date: February 9, 2017
    Applicants: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Xin LI, Wei HE, Xianbo LIU, Bin WANG, Qiyue HU, Fangfang JIN, Qing DONG, Piaoyang SUN
  • Publication number: 20160108035
    Abstract: Cycloalkyl acid derivatives, a preparation method thereof, and a pharmaceutical application thereof are described. In particular, a cycloalkyl acid derivative represented by general formula (I) and a medical salt thereof, a preparation method thereof, and an application of the cycloalkyl acid derivative and the medical salt thereof as URAT1 inhibitors, and particularly as therapeutic agents for diseases related to an abnormal uric acid level are described, wherein definitions of substituent groups in general formula (I) are the same as the definitions in the specification.
    Type: Application
    Filed: April 29, 2014
    Publication date: April 21, 2016
    Applicant: Shanghai Hengrui Pharmaceutical Co., Lt.d
    Inventors: Jianbiao PENG, Piaoyang SUN, Jiong LAN, Chunyan GU, Xiaotao LI, Bonian LIU, Chunzhou HAN, Qiyue HU, Fangfang JIN, Qing DONG, Guoqing CAO
  • Publication number: 20100137283
    Abstract: The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIV”) integrase enzyme.
    Type: Application
    Filed: February 1, 2010
    Publication date: June 3, 2010
    Inventors: Klaus Ruprecht Dress, Qiyue Hu, Ted William Johnson, Michael Bruno Plewe, Steven Paul Tanis, Huichun Zhu, Junhu Zhang
  • Patent number: 7692014
    Abstract: The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIV”) integrase enzyme.
    Type: Grant
    Filed: April 25, 2005
    Date of Patent: April 6, 2010
    Assignee: Pfizer, Inc.
    Inventors: Klaus Ruprecht Dress, Qiyue Hu, Ted William Johnson, Michael Bruno Plewe, Steven Paul Tanis, Huichun Zhu, Junhu Zhang
  • Patent number: 7468375
    Abstract: The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIV”) integrase enzyme.
    Type: Grant
    Filed: April 25, 2005
    Date of Patent: December 23, 2008
    Assignee: Pfizer Inc.
    Inventors: Klaus Ruprecht Dress, Qiyue Hu, Ted William Johnson, Michael Bruno Plewe, Steven Paul Tanis, Hai Wang, Anle Yang, Chunfeng Yin, Junhu Zhang
  • Publication number: 20080221154
    Abstract: Bicyclic hydroxamate compounds represented by the Formula I: are described. The bicyclic hydroxamate compounds and compositions containing those compounds may be used to inhibit or modulate an enzyme activity of HIV Integrase and to treat HIV mediated diseases and conditions.
    Type: Application
    Filed: March 6, 2008
    Publication date: September 11, 2008
    Inventors: Qiyue HU, Ted William Johnson, Atsuo Kuki, Michael Bruno Plewe, Dawn Marie Nowlin, Hai Wang, Junhu Zhang
  • Patent number: 7368571
    Abstract: Bicycling hydroxamate compounds represented by the Formula I: are described. The bicyclic hydroxamate compounds and compositions containing those compounds may be used to inhibit or modulate an enzyme activity of HIV Integrase and to treat HIV mediated diseases and conditions.
    Type: Grant
    Filed: September 6, 2006
    Date of Patent: May 6, 2008
    Assignee: Pfizer Inc
    Inventors: Qiyue Hu, Atsuo Kuki, Dawn Marie Nowlin, Michael Bruno Plewe, Hai Wang, Junhu Zhang